Evidence map›Paper›PMID 35882977›Full record

ArticleScientific reports2022

Label-free viability assay using in-line holographic video microscopy.

Rostislav Boltyanskiy, Mary Ann Odete, Fook Chiong Cheong, Laura A Philips

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Rostislav Boltyanskiy *Spheryx, Inc., New York, NY, 10016, USA. rboltyanskiy@spheryx.solutions.
Mary Ann Odete *Spheryx, Inc., New York, NY, 10016, USA.
Fook Chiong CheongSpheryx, Inc., New York, NY, 10016, USA.
Laura A PhilipsSpheryx, Inc., New York, NY, 10016, USA.
Spheryx (United States) · US

Funding

Instrument for Holographic Characterization of Protein Aggregates - This SBIR Phase II program is developing an instrument that uses holographic video microscopy to meet quality needs for biologics.R44TR001590 · NCATS · SPHERYX, INC. · PI PHILIPS, LAURA A · 2017 to 2021
$3.6M
NCATS NIH HHS R44TR001590
6 · The paper itself

Abstract

Total holographic characterization (THC) is presented here as an efficient, automated, label-free method of accurately identifying cell viability. THC is a single-particle characterization technology that determines the size and index of refraction of individual particles using the Lorenz-Mie theory of light scattering. Although assessment of cell viability is a challenge in many applications, including biologics manufacturing, traditional approaches often include unreliable labeling with dyes and/or time consuming methods of manually counting cells. In this work we measured the viability of Saccharomyces cerevisiae yeast in the presence of various concentrations of isopropanol as a function of time. All THC measurements were performed in the native environment of the sample with no dilution or addition of labels. Holographic measurements were made with an in-line holographic microscope using a 40[Formula: see text] objective lens with plane wave illumination. We compared our results with THC to manual counting of living and dead cells as distinguished with trypan blue dye. Our findings demonstrate that THC can effectively distinguish living and dead yeast cells by the index of refraction of individual cells.

Indexed as

HolographySaccharomyces cerevisiaeColoring AgentsMicroscopyMicroscopy, VideoColoring Agents

Identifiers

PMID35882977
PMCPMC9325748
OpenAlexW4288181016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.